Is the price fair?
What CORT's price assumes
Corcept Therapeutics Incorporated trades at 325× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
325
Trailing P/E · Biotechnology median 31.5 · 10.3× the median: the market pays up for this one
- Price / sales
- 5.47
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.3%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +23%
Growth the price implies · The price pays for +23% free cash flow growth a year for a decade; the business has delivered +2.8% a year over the last three.
Details›
- Price / book2026-Q1
- 6.60
- EV / EBIToperating margin −1.1%: the multiple describes the denominator
- not meaningful
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $120M
- Market capitalisation
- $9.10B
- 3-year revenue growth
- +23%
- 3-year free cash flow growth
- +2.8%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 79.7× today against a 26.9× median |
| 52-week range | $32.15 – $123.53 |
| Today | $113.90 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.